In collaboration with a bio-venture capital fund manager, the Swiss lender has raised US$340 million in the first round of a project for the betterment of cancer treatment. This project comes as another push for the expansion of the impact investment universe in Asia Pacific, a nascent space in the region. This project with MPM Capital sets out to make…
To access this content, please click back to the home screen, then click “Menu” (bars in top left bars) and then “Login”.
To enquire for a free trial, please start here.
Need more help? Click here or email [email protected].
To enquire for a free trial, please start here.
Need more help? Click here or email [email protected].
Subscriber Only Content
This article is available on a corporate subscription with Asian Private Banker. Please login or subscribe to view this content.
Need help? Please see our FAQ Guide or email [email protected]
Have a confidential tip? Get in touch [email protected]
